Basic Information
| LncRNA/CircRNA Name | NCK-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot analysis, Dual Luciferase Reporter Assay, RIP |
| Sample | Osteosarcoma cell lines (MG63, KHOS and U2OS) and the normal osteoblastic cell line (hFOB) |
| Expression Pattern | up-regulated |
| Function Description | NCK1-AS1 was significantly upregulated in osteosarcoma cells, as well as in DDP-resistant osteosarcoma cells. NCK1-AS1 silence inhibited the proliferation, migration and invasion of osteosarcoma cells, whereas enhanced the sensitivity of osteosarcoma cells to DDP. Furthermore, NCK1-AS1 directly interacted with miR-137 and overexpression of miR-137 suppressed the proliferation, migration and invasion of osteosarcoma cells. |
| Pubmed ID | 31908475 |
| Year | 2019 |
| Title | Knockdown Of lncRNA NCK-AS1 Regulates Cisplatin Resistance Through Modulating miR-137 In Osteosarcoma Cells |
External Links
| Links for NCK-AS1 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |